A major trial of the oral drug Cladribine – has shown that it significantly reduces relapse and deterioration of the disease,eliminating the unpleasant side effects with present medication according to The New England Journal of Medicine on 20 January 2010.
Cladribine is vying to be the first ever treatment in tablet form for MS,relatively few side effects,make it a hugely exciting development in the world of MS.
Its taken for between 8 to 10 days a year,avoiding the need for regular injections and intravenous infusions.
Professor Giovanonni said: "The introduction of an oral therapy, particularly one that has no short term side effects and is as easy to use as oral Cladribine, will have a major impact on the treatment of MS.
"However, the use of this drug as a first line therapy will have to be weighed up against the potential long term risks which have yet to be defined."
Source: Queen Mary, University of London © Disabled World 2010 (21/01/10)
Monday, January 25, 2010
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment